The EPO published international patent application EP4480952A1 designating 44 contracting states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR). The patent protects a crystalline heterocyclic compound classified under C07D471/04 and C07D487/04 with pharmaceutical composition claims targeting cancer (A61P35/00). Inventors include GONG Wanchun, LI Di, LI Ruipeng, DUAN Lingjun, XIA Guangxin, and KE Ying.

This is a standard patent publication with no immediate regulatory obligations. Pharmaceutical companies developing similar heterocyclic compounds should conduct freedom-to-operate analyses to assess potential infringement risks. Patent prosecution will continue through the EPO examination process, with applicants able to validate the patent in any combination of designated contracting states upon grant.